Who makes Refresh Optive Mega-3 PF?

Refresh Optive Mega-3 PF is developed by University of California, Berkeley.

What development phase is Refresh Optive Mega-3 PF in?

Refresh Optive Mega-3 PF is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Refresh Optive Mega-3 PF

University of California, Berkeley · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Refresh Optive Mega-3 PF
Sponsor	University of California, Berkeley
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Artificial Tears, Tear Lipids and Tear Film Dynamics (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Refresh Optive Mega-3 PF CI brief — competitive landscape report
Refresh Optive Mega-3 PF updates RSS · CI watch RSS
University of California, Berkeley portfolio CI